Domača stranSDZ • SWX
add
Sandoz
Prejšnji trg. dan.
48,25 CHF
Dnevni razpon
47,55 CHF - 48,25 CHF
Letni razpon
26,25 CHF - 50,88 CHF
Tržna kapitalizacija
20,97 mrd. CHF
Povprečni obseg
831,16 tis.
Razm. P/E
116,00
Dividendna donosnost
1,25 %
Primarna borza
SWX
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 2,63 mrd. | 4,01 % |
Stroški poslovanja | 904,50 mio. | −11,67 % |
Čisti dohodek | 188,50 mio. | 151,33 % |
Čista dobičkovnost prihodkov | 7,16 | 141,89 % |
Earnings per share | — | — |
EBITDA | 415,00 mio. | 53,42 % |
Efektivna davčna stopnja | 25,20 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 1,39 mrd. | 98,15 % |
Skupna sredstva | 21,61 mrd. | 11,86 % |
Skupne obveznosti | 12,79 mrd. | 16,79 % |
Celoten lastniški kapital | 8,82 mrd. | — |
Shares outstanding | 432,00 mio. | — |
Razmerje P/B | 2,36 | — |
Donosnost sredstev | 3,48 % | — |
Donosnost kapitala | 5,18 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | jun. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 188,50 mio. | 151,33 % |
Denar iz dejavnosti | 261,50 mio. | 128,38 % |
Denar iz naložb | −158,00 mio. | 19,80 % |
Denar iz financiranja | −74,00 mio. | 35,09 % |
Neto sprememba denarnih sredstev | 99,00 mio. | 148,53 % |
Prost denarni tok | 151,94 mio. | 47,69 % |
Vizitka
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkichen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars. Wikipedia
Generalni direktor
Datum ustanovitve
1886
Spletno mesto
Zaposleni
20.000
